TITLE

The Food and Drug Administration Amendments Act of 2007: Drug safety and health-system pharmacy implications

AUTHOR(S)
Meyer, Brian M.
PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. To describe the drug safety provisions of the Food and Drug Administration Amendments Act (FDAAA) of 2007, including risk evaluation and mitigation strategies (REMS), and the implications for health-system pharmacists. Summary. The FDAAA grants FDA new authorities to require postmarketing studies or clinical trials of human drugs and to require REMS. The REMS provisions of the FDAAA represent the evolution of FDA drug safety requirements. Components of REMS include medication guides, patient package inserts, and communication plans for health care providers. For medications with known safety risks, the FDAAA requires the inclusion in the REMS process of elements to ensure safe use. These elements may include special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. Conclusion. Standardization of elements to ensure the safe use of drugs with known serious risks is needed so that REMS are not unduly burdensome for the health care delivery system and do not needlessly limit patient access to the drugs.
ACCESSION #
48713390

 

Related Articles

  • The Food and Drug Administration Amendments Act of 2007: Drug safety and health-system pharmacy implications. Shane, Rita // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS2 

    The article examines the implications upon drug safety and health-system pharmacies as a result of the implementation of the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007. The author asserts that the FDAAA enhanced the authority of the FDA during postmarketing of drugs, which...

  • Ensuring drug safety in health systems: Role of the Food and Drug Administration Amendments Act of 2007, risk evaluation and mitigation strategies, and restricted drug distribution systems.  // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS21 

    The article presents several learning objectives and assessment questions for readers of the journal upon completion of the articles in the November 15, 2009, issue. The article states that readers should be able to discuss various provisions of the U.S. Food and Drug Administration Amendments...

  • Specialty pharmacies and other restricted drug distribution systems: Financial and safety considerations for patients and health-system pharmacists. Kirschenbaum, Bonnie E. // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS13 

    Purpose. To discuss the role of restricted drug distribution systems in the implementation of risk evaluation and mitigation strategies (REMS), health-system pharmacists’ concerns associated with the use of specialty pharmacies and other restricted drug distribution systems, reimbursement...

  • APhA-APRS. Williams, Karl G. // Journal of the American Pharmacists Association: JAPhA;Sep/Oct2010, Vol. 50 Issue 5, p560 

    The article discusses new provisions in the United States Food and Drug Administration Amendments Act (the Act) . The Act authorizes the Food and Drug Administration (FDA) to require submission of a proposed risk evaluation and mitigation strategies (REMS) by manufacturers any time that risks of...

  • Fresh from the biologic pipeline. Osborne, Randall // Nature Biotechnology;Mar2009, Vol. 27 Issue 3, p222 

    The article discusses the approval of numerous molecular entities by the U.S. Food and Drug Administration (FDA), which took place in 2008. Many new rules have stemmed from legislation concerning the government entity, including the Food and Drug Administration Amendments Act (FDAAA) that was...

  • OIG: Who Knows Whether REMS Improve Drug Safety? Serebrov, Mari // BioWorld Today;2/14/2013, Vol. 24 Issue 31, p1 

    The article offers the author's insights on the effectiveness of risk evaluation and mitigation strategies (REMS) in assuring drug safety. The author says that based on the Office of the Inspector General's (OIG's) report on February 13, 2013, there is no reliable method identified to assess the...

  • Record high drug shortages warrant FDA policy changes, AHA tells House health panel.  // AHA News;7/11/2011, Vol. 47 Issue 14, p1 

    The article reports on the action of the U.S. Food and Drug Administration to avoid drug shortages, such as the implementation of the Prescription Drug User Fee Act and the Preserving Access to Life Saving Medications Act.

  • FDA May Alter Rules on Drug Combos.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to change rules enabling manufacturers greater leeway in developing drug combinations.

  • FDA Actions.  // CenterWatch Monthly;Nov2015, Vol. 22 Issue 11, p16 

    A chart is presented depicting a sampling of the U.S. Food and Drug Administration (FDA) regulatory actions taken during October 2015.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics